Augmedix, Inc. (AUGX) | Investment Case

1. Company Snapshot

1.a. Company Description

Augmedix, Inc.provides remote medical documentation solutions and live clinical support services in the United States.Its platform offers Augmedix Live and Augmedix Notes solutions that provide pre-visit documentation, such as pre-charting and digitization of previous records/patient history; during-visit documentation, including medical notes, care gap reminders, HCC reminders, and after-visit summaries; and post-visit documentation consisting of coding, orders, and referrals.

The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass.It serves health systems and specialty groups.The company was founded in 2013 and is headquartered in San Francisco, California.

Show Full description

1.b. Last Insights on AUGX

Augmedix's recent performance was driven by a substantial announcement on July 19, 2024, where the company revealed its partnership with Commure, a healthcare technology company, to strengthen its ability to deliver frontier ambient AI solutions. The partnership led to an all-cash acquisition by Commure, where Augmedix stockholders received $2.35 per share. Additionally, the company reported a 27% revenue growth for the second quarter of 2024, showcasing its growth potential.

1.c. Company Highlights

Last Price	2.35
Change Percentage	-0.21%
Open	2.34
Previous Close	2.35
Market Cap ( Millions)	116
Volume	22995
Year High	6.25
Year Low	0.73
M A 50	2.29
M A 200	3.01

FCF Yield	-16.00%
Dividend Yield	0.00%
ROE	-154.69%
Debt / Equity	117.23%
Net Debt / EBIDTA	121.22%
Price To Book	4.42
Price Earnings Ratio	-5.38
Price To FCF	-6.25
Price To sales	2.58
EV / EBITDA	-6.18

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Commure Completes Merger with Augmedix

Oct -02

Source: globenewswire.com

7 AI Penny Stocks to Watch in October

Sep -27

Source: 247wallst.com

INVESTIGATION: The M&A Class Action Firm Investigates the Merger and Imminent Vote on September 20, 2024, of Squarespace, Inc. - SQSP

Sep -06

Source: prnewswire.com

Augmedix, Inc. (AUGX) Reports Q2 Loss, Lags Revenue Estimates

Aug -12

Source: zacks.com

Augmedix Delivers 27% Revenue Growth for Second Quarter of 2024

Aug -12

Source: globenewswire.com

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Premier Financial Corp. – PFC

Jul -30

Source: globenewswire.com

Why Is Augmedix (AUGX) Stock Up 150% Today?

Jul -19

Source: investorplace.com

Shareholder Alert: Ademi LLP investigates whether Augmedix, Inc. has obtained a Fair Price for its Public Shareholders

Jul -19

Source: prnewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.00%)

6. Segments

Ambient Artificial Intelligence Documentation and Data Solutions

Expected Growth: 8%

Augmedix's Ambient Artificial Intelligence Documentation and Data Solutions drive 8% growth through increased adoption in healthcare, driven by need for efficient clinical documentation, growing demand for AI-powered data analytics, and expansion into new markets, such as medical research and telemedicine.

7. Detailed Products

Augmedix Platform

A cloud-based platform that uses AI-powered automation to streamline medical documentation, allowing clinicians to focus on patient care.

Ambulatory EHR Services

A comprehensive electronic health record (EHR) solution for ambulatory care, offering seamless integration with existing systems and workflows.

Revenue Cycle Management (RCM) Services

A comprehensive RCM solution that leverages AI-powered automation to optimize revenue cycle operations, including coding, billing, and claims management.

Clinical Documentation Improvement (CDI) Services

A CDI solution that uses AI-powered technology to identify and address documentation gaps, ensuring accurate and comprehensive clinical documentation.

Data Analytics and Insights

A data analytics platform that provides actionable insights to healthcare organizations, enabling data-driven decision-making and quality improvement.

8. Augmedix, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Augmedix's AI-powered medical note-taking technology is highly specialized, making it difficult for substitutes to emerge.

Bargaining Power Of Customers

While customers have some bargaining power due to the competitive healthcare industry, Augmedix's unique technology and partnerships with major health systems mitigate this power.

Bargaining Power Of Suppliers

Augmedix's technology is largely developed in-house, reducing dependence on suppliers and minimizing their bargaining power.

Threat Of New Entrants

The healthcare technology industry is rapidly evolving, and new entrants with similar AI-powered solutions could potentially disrupt Augmedix's market share.

Intensity Of Rivalry

While there is some competition in the medical note-taking space, Augmedix's established partnerships and proprietary technology give it a competitive edge.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	48.31%
Debt Cost	4.27%
Equity Weight	51.69%
Equity Cost	4.27%
WACC	4.27%
Leverage	93.47%

11. Quality Control: Augmedix, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Accolade

A-Score: 4.7/10

Value: 8.3

Growth: 5.8

Quality: 3.8

Yield: 0.0

Momentum: 9.5

Volatility: 0.7

1-Year Total Return ->

OptimizeRx

A-Score: 4.3/10

Value: 2.7

Growth: 6.0

Quality: 6.1

Yield: 0.0

Momentum: 10.0

Volatility: 1.0

1-Year Total Return ->

Teladoc Health

A-Score: 4.0/10

Value: 9.6

Growth: 5.1

Quality: 4.4

Yield: 0.0

Momentum: 2.0

Volatility: 3.0

1-Year Total Return ->

Health Catalyst

A-Score: 3.7/10

Value: 9.8

Growth: 5.6

Quality: 4.3

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

Augmedix

A-Score: 3.6/10

Value: 7.2

Growth: 4.6

Quality: 3.9

Yield: 0.0

Momentum: 6.0

Volatility: 0.0

1-Year Total Return ->

Schrödinger

A-Score: 3.0/10

Value: 4.8

Growth: 2.8

Quality: 3.9

Yield: 0.0

Momentum: 3.5

Volatility: 3.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

13.01%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

4.27%

Augmedix, Inc. - US05105P1075

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on AUGX

1.c. Company Highlights

Stable Momentum

Medium Volatility

Average Quality

Revenues Miss

Fairly Valued

More Volatile

Earnings Miss

Average Yield

Earnings Beats

Lower Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.00%)

6. Segments

Ambient Artificial Intelligence Documentation and Data Solutions

Expected Growth: 8%

7. Detailed Products

Augmedix Platform

Ambulatory EHR Services

Revenue Cycle Management (RCM) Services

Clinical Documentation Improvement (CDI) Services

Data Analytics and Insights

8. Augmedix, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Augmedix, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.34$

Current Price

2.35$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA